Synteract is opening a new office in Swansea, Wales in response to increased demand across its core therapeutic areas for both full-service work and more consultative, standalone projects, says CEO.
There is a common and often unchallenged perception that manufacturing quality standards in pharmerging countries are worrisome, but Lee Newton of Lonza argues this is not the reality.
The global software consulting company N-Side recently launched an end-to-end clinical trial supply chain management solution to enable “agile” decision making and reduce drug waste.
US FDA announces that a new generic for valsartan will reach the market, after prioritising the review of the product to alleviate shortages resulting from recalled products.
The institutional review board industry sees further consolidation as Advarra acquires Quorum and its research and technology consulting division, Kinetiq.
The pharmaceutical and biotech consultancy has opened a new office in Dublin, Ireland ahead of Brexit, the final outcomes of which remain unknown, says CEO.
The introduction of the SPC manufacturing waiver will generate billions in export sales and create a number of jobs across the EU, suggests Medicines for Europe.
Hugh Pullen, EMVO’s president, explains what the launching of the EMVS means for the industry, and details how a potential no-deal Brexit will impact the system.
France, Germany, and the UK recently formed INSTEX to be able to secure trade despite US sanctions on Iran, a move that has been welcomed by Novo Nordisk.
The EMA’s investigation into ‘sartan’ medicines has concluded, requiring companies to review processing procedures and prove products are without impurities.
The Wasdell Group’s new EU headquarters in Dundalk, Ireland is set to commence operations later this year as part of the company’s “proactive contingency plan” ahead of Brexit.
European generics industry faces opposition while pushing for the SPC manufacturing waiver to be altered so it allows for the production of drugs under patent for non-EU countries.
August Research is adding clinical trial operations in Georgia and Moldova, expanding the CRO’s reach in Central and Eastern Europe – a less developed market with “fewer competitive trials and lower costs,” says CEO.
The two companies will combine technologies to create solid-dose, needle-free vaccines for a number of infectious diseases and emergent threat pathogens.
The more outsourcing experience a pharma company has, the less important its proximity to contract manufacturing partners becomes, outlines Novo Nordisk VP.
The Indian government seeks to boost local drug production by stipulating that the ‘local content’ of domestic products is 75% and 10% for those that are non-domestic.
Parexel and Eli Lilly are launching a clinical research learning and development program in China as recent reforms have “dramatically” increased the need for new sites in the country.
ARG has made the move across the Atlantic, establishing its first office outside of the US following its acquisition of the UK-based CRO CCA Clinical Research.
Pharma companies have improved or maintained standards for effective drug recalls, product packaging and managing supply in LMICs, according to the report.
Moving forward, China will take a more integral role in global drug development, following several regulatory changes designed to accelerate innovation.
Scientist.com has more than 70 employees across the globe, with offices in San Diego, Boston, the UK – and soon, Japan, with plans to open several satellite offices across the country.
Charles River is eyeing M&A opportunities in every segment of its business, fueled by global market demand and a “fundamental shift” in the pharmaceutical industry, says CEO.
Marken is centralizing its brokerage management services in conjunction with UPS, as the rise in global trials brings more vendors and new challenges into the fold.
As negotiations continue and discussions on ‘hard Brexit’ outcomes build, few have considered the impact on European industry, one organisation suggests.